Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism

Movement Disorders

Volumn 17, Issue 6, 2002, Pages 1265-1270

  Feigin, Andrew ^a   Antonini, Angelo ^b   Fukuda, Masafumi ^a   De Notaris, Roberta ^b   Benti, Riccardo ^b   Pezzoli, Gianni ^b   Mentis, Marc J ^a   Moeller, James R ^c   Eidelberg, David ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b PARKINSON INSTITUTE   (Italy)

^c Columbia Col of Physicians/Surgeons ^*  (United States)

Author keywords

Differential diagnosis; ECD SPECT; Network analysis; Parkinsonism

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M;

ADULT; AGED; BASAL GANGLION; BRAIN PERFUSION; CALCULATION; CEREBELLUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; FRONTAL LOBE; HUMAN; IMAGE ANALYSIS; MALE; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL LOBE; THALAMUS;

AGED; BRAIN; CYSTEINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NERVE NET; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; REGIONAL BLOOD FLOW; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036868515     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10270     Document Type: Review

References (32)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological, and neurochemical correlations. J Neurol Sci 1973;20:415-455.
2. Wichmann T, DeLong MR. Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996;6:751-758.
3. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213.
4. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994; 14:783-801.
5. Eidelberg D, Edwards C, Mentis MJ, Dhawan V, Moeller JR. Movement disorders: Parkinson's disease. In: Mazziota JC, Toga AW, Frackowiak RSJ, editors. Brain mapping: the disorders. San Diego: Academic Press, 2000. p 241-261.
6. Moeller JR, Nakamura T, Mentis M, et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 1999;40:1264-1269.
7. Eidelberg D, Moeller JR, Ishikawa T, et al. Assessment of disease severity in parkinsonism with fluorine- 18- fluorodeoxyglucose and PET. J Nucl Med 1995;36:378-383.
8. Moeller JR, Eidelberg D. Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing. Brain 1997; 120(Pt 12):2197-2206.
9. Fukuda M, Mentis MJ, Ma Y, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting state glucose metabolism. Brain 2001;124: 1601-1609.
10. Feigin A, Mentis MJ, Dhawan V, Margouleff C, Eidelberg D. Levodopa infusion reduces the expression of a Parkinson's disease metabolic brain network: an FDG PET study. Neurology 2000;54(Suppl. 3):A113.
11. Eidelberg D, Dhawan V, Moeller JR, et al. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991;54:856-862.
12. DeVolder AG, Francart J, Laterre C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 1989;26:239-247.
13. Eidelberg D, Takikawa S, Moeller JR, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993;33:518-527.
14. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 1994;36:166-175.
15. Antonini A, Kazumata K, Feigin A, et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord 1998;13:268-274.
16. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with 18F- fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
17. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000;55:1540-1547.
18. Quinn N. Multiple system atrophy: the nature of the beast. J Neurol Neurosurg Psychiatry 1989;52:78-89.
19. Quinn N, Marsden CD. The motor disorder of multiple system atrophy. J Neurol Neurosurg Psychiatry 1993;56:1239-1242.
20. Eidelberg D, Moeller JR, Kazumata K, et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 1997; 120(Pt 8):1315-1324.
21. Alexander GE, Moeller JR. Application of the scaled subprofile model to functional imaging in neuropsychiatric disorders: a principal component approach to modeling brain function in disease. Hum Brain Map 1994;2:1-16.
22. Moeller JR, Ishikawa T, Dhawan V, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab 1996;16:385-398.
23. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-298.
24. Eidelberg D, Moeller JR, Ishikawa T, et al. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. Ann Neurol 1996;39:450-459.
25. Su P, Ma Y, Fukuda M, et al. Metabolic changes following subthalamotomy for advanced Parkinson's disease. Ann Neurol 2001;50:514-570.
26. Jueptner M, Weiller C. Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Neuroimage 1995;2:148-156.
27. Villringer A, Dirnagl U. Coupling of brain activity and cerebral blood flow: basis of functional neuroimaging. Cerebrovasc Brain Metab Rev 1995;7:240-276.
28. Barbier EL, Lamalle L, Decorps M. Methodology of brain perfusion imaging. J Magn Reson Imag 2001;13:496-520.
29. Calamante F, Thomas DL, Pell GS, Wiersma J, Turner R. Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab 1999;19:701-735.
30. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
31. Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G. Measuring the progression of idiopathic Parkinson's disease with [123I]β-CIT SPECT. J Neural Transm 2000;107:543-552.
32. Pirker W, Asenbaum S, Bencsits G, et al. [123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-1167.